MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PIRAMAL ENTERPRISES LTD. (pharmaceuticals)
- Latest 8 Quarter Result
Piramal Healthcare Quarterly Results (NCHP)
Here are the latest quarterly results of Piramal Healthcare. For more details, see the Piramal Healthcare financial fact sheet and Piramal Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.
Piramal Healthcare Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 29,911 | 29,025 | 31,441 | 34,891 | 36,797 | 35,063 | 36,036 | 38,057 | |
| Other income | Rs m | 365 | 144 | 563 | 1,028 | 852 | 669 | 627 | 1,413 | |
| Turnover | Rs m | 30,276 | 29,169 | 32,004 | 35,919 | 37,649 | 35,732 | 36,662 | 39,470 | |
| Expenses | Rs m | 16,103 | 13,758 | 14,911 | 14,618 | 17,380 | 14,004 | 13,497 | 15,099 | |
| Gross profit | Rs m | 14,732 | 10,744 | 17,264 | 20,273 | 19,283 | 20,945 | 22,398 | 22,958 | |
| Depreciation | Rs m | 1,151 | 1,288 | 1,234 | 1,326 | 1,354 | 1,582 | 1,664 | 1,664 | |
| Interest | Rs m | 8,306 | 9,091 | 10,162 | 11,688 | 13,157 | 14,085 | 14,182 | 14,417 | |
| Profit before tax | Rs m | 5,640 | 510 | 6,432 | 8,287 | 5,624 | 5,947 | 7,179 | 8,289 | |
| Tax | Rs m | -33,800 | 1,810 | 1,628 | 2,930 | 2,243 | 2,176 | 1,581 | 2,306 | |
| Profit after tax | Rs m | 39,440 | -1,300 | 4,804 | 5,356 | 3,381 | 3,771 | 5,598 | 5,983 | |
| Gross profit margin | % | 49.3 | 37.0 | 54.9 | 58.1 | 52.4 | 59.7 | 62.2 | 60.3 | |
| Effective tax rate | % | -599.3 | 355.1 | 25.3 | 35.4 | 39.9 | 36.6 | 22.0 | 27.8 | |
| Net profit margin | % | 131.9 | -4.5 | 15.3 | 15.4 | 9.2 | 10.8 | 15.5 | 15.7 | |
| Diluted EPS | Rs | 228.6 | -7.5 | 27.8 | 31.0 | 19.6 | 21.9 | 32.4 | 34.7 | |
| Diluted EPS (TTM) | Rs | 285.8 | 264.0 | 274.3 | 279.9 | 70.9 | 100.3 | 104.9 | 108.6 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Piramal Healthcare 3QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: STRIDES PHARMA SCIENCE PFIZER INDOCO REMEDIES TTK HEALTHCARE PANACEA BIOTECH
Compare PIRAMAL ENTERPRISES With: STRIDES PHARMA SCIENCE PFIZER INDOCO REMEDIES TTK HEALTHCARE PANACEA BIOTECH
Compare PIRAMAL ENTERPRISES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)
Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.
Views on news
PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)
Feb 5, 2020 | Updated on Feb 5, 2020For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)
Oct 25, 2019 | Updated on Oct 25, 2019For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)
Jul 9, 2019 | Updated on Jul 9, 2019Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.
More Views on NewsMost Popular
Sorry Warren Buffett, I'm Following This Man Instead of You in 2020 (The 5 Minute Wrapup)
Mar 30, 2020This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...
A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
The Biggest Trading Opportunity of 2020 is Here...
Mar 26, 2020India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!
Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock (Profit Hunter)
Mar 24, 2020Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.
Lockdown! Now the Bailout... (The Honest Truth)
Mar 25, 2020Ajit Dayal on what India should do to manage the coronavirus impact on the economy.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
PIRAMAL ENTERPRISES SHARE PRICE
Apr 1, 2020 (Close)
TRACK PIRAMAL ENTERPRISES
- Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PIRAMAL ENTERPRISES
PIRAMAL ENTERPRISES 5-YR ANALYSIS
COMPARE PIRAMAL ENTERPRISES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.